Biocardia Inc stock is traded at $0.9101, with a volume of 28,833. It is up +2.25% in the last 24 hours and down -14.15% over the past month. BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Previous Close:
$0.89
Open:
$0.9299
24h Volume:
28,833
Relative Volume:
0.38
Market Cap:
$13.78M
Revenue:
$3,000
Net Income/Loss:
-$7.78M
P/E Ratio:
-
EPS:
-$1.03
Net Cash Flow:
-$7.49M
1W Performance:
+5.70%
1M Performance:
-14.15%
6M Performance:
-18.01%
1Y Performance:
-28.90%
1-Day Range:
$0.8801$0.93
1-Week Range:
$0.8359$0.9999
52-Week Range:
$0.75$1.80
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia IncSector
HealthcareIndustry
BiotechnologyPhone
650-226-0123Address
320 SOQUEL WAY, SUNNYVALE, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS